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In 2007, a European survey identified variation in 
country policies on public health management of inva-
sive meningococcal disease (IMD). In 2009–10, the 
European Centre for Disease Prevention and Control 
(ECDC) published evidence-based guidance on IMD. 
We therefore surveyed again European countries to 
describe policies for managing IMD cases and con-
tacts in 2013. We asked national IMD public health 
experts from 32 European countries to complete a 
questionnaire focusing on post-exposure prophylaxis 
(PEP) for IMD contacts and meningococcal vaccination. 
Proportions in 2007 and 2013 were compared using 
the chi-squared test. All 32 countries responded, with 
responses from two regions for Belgium and Italy; half 
stated having used ECDC guidance to update national 
recommendations. PEP was recommended to close 
contacts in 33 of 34 countries/regions, mainly cipro-
floxacin for adults (29/32 countries) and rifampicin for 
children (29/32 countries). ECDC guidance for manag-
ing IMD contacts in airplanes was strictly followed by 
five countries/regions. Twenty-three countries/regions 
participated in both surveys. Compared with 2007, in 
2013, more countries/regions recommended i) cef-
triaxone for children (15/23 vs 6/20; p = 0.03), ii) PEP 
for all children in the same preschool group (8/23 vs 
17/23; p = 0.02). More countries/regions recommended 
evidence-based measures for IMD public health man-
agement in 2013 than 2007. However, some discrepan-
cies remain and they call for further harmonisation.
Introduction
Invasive meningococcal disease (IMD) is associated 
with high case fatality (9% in 26 European countries 
in 2011 [1]) and substantial risk of long-term sequelae 
among survivors [2-4]. This explains the high level of 
concern associated with cases of IMD despite a low inci-
dence in Europe of under one case per 100,000 popula-
tion annually in the past decade [4,5]. Close contacts 
of IMD patients have a 200- to 1,200-fold increased 
risk of developing the disease [6-9]. Post-exposure 
prophylaxis (PEP) and, in case of a vaccine-preventa-
ble strain in the index case, vaccination of close con-
tacts, are evidence-based measures to reduce the risk 
of secondary IMD cases. However, while the former is 
based on direct evidence showing decreased incidence 
among household contacts if they receive PEP [10], 
the latter rests on indirect evidence only, consisting of 
the observed increased risk for IMD in household con-
tacts despite chemoprophylaxis during the 14 to 365 
days after contact with the index case [7,11]. A survey 
in 2007, performed by the public health management 
working group of the European Meningococcal Disease 
Society (EMGM), documented that recommendation of 
these and other public health control measures varied 
widely among European countries [12]. This heteroge-
neity was thought to reflect uncertainty on effective-
ness of public health measures, but also pragmatic, 
economic or legal constraints of policymakers in differ-
ent countries.
A consistent and evidence-based public health policy 
on the management of IMD cases and their contacts 
across Europe is desirable to facilitate communica-
tion among countries in case of cross border case 
management. Therefore, the EMGM working group 
developed evidence based guidance for good prac-
tice in public health management of sporadic cases of 
meningococcal disease and their contacts [10]. In 2010, 
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this document was adopted as European Centre for 
Disease Prevention and Control (ECDC) guidance [10]. 
In addition, in 2009–10, risk assessment guidelines 
for diseases transmitted on aircraft (RAGIDA) includ-
ing recommendations on the management of contacts 
to an IMD case were published by ECDC [13,14] (Box). 
The EMGM working group repeated the survey on IMD 
public health policies in 2013. Our objectives were to 
describe current public health policies for managing 
cases of meningococcal disease and their contacts in 
European countries, to track changes in national public 
health policies since 2007 and to assess to what extent 
measures outlined in the ECDC guidance were imple-
mented in the respective countries.
Methods
We conducted a cross-sectional study, addressing 
32 national IMD public health experts from all 28 
European Union (EU) Member States and four European 
Free Trade Association (EFTA) countries (Iceland, 
Liechtenstein, Norway, and Switzerland). Participants 
from national public health institutes were identi-
fied from the previous survey in 2007 and from mem-
ber lists of the ECDC Vaccine Preventable Diseases 
Network and EMGM. We invited potential participants 
via email to complete either a word or a web-based 
version (voozanoo by Epiconcept) of a structured ques-
tionnaire. The questionnaire comprised 40 questions 
and covered the following topics: clinical and labora-
tory diagnostic case definition criteria for confirmation 
of a case; the definition of a close contact for control 
measures; the use and choice of PEP for persons with 
contact to IMD cases in different settings; the use of 
meningococcal vaccines in routine schedules and after 
exposure to an IMD case; the perceived usefulness of 
the ECDC guidance document in updating national rec-
ommendations. The questionnaire was similar to the 
one used in 2007, but questions on criteria for defin-
ing cases and contacts and on policies for managing 
contacts in school and day care settings as well as 
in transport vehicles were expanded (questionnaire 
available from the authors upon request). Comparison 
of answers between 2007 and 2013 was restricted to 
countries participating in both surveys. Countries with 
missing data for a particular item were excluded when 
calculating proportions. Proportions were compared 
using chi-squared and Fisher’s exact tests. Differences 
were considered statistically significant at p < 0.05.
Results
All 32 countries responded to the 2013 survey. Two 
responses each were obtained from Belgium and Italy, 
reflecting sub-national policies. These were included 
as separate entities in the analysis, bringing the total 
number of respondents to 34. The following 23 of the 34 
countries/regions responded to both surveys: Austria, 
Belgium (Flanders and Wallonia), Czech Republic, 
Denmark, Estonia, Finland, France, Germany, Hungary, 
Iceland, Ireland, Lithuania, Malta, the Netherlands, 
Norway, Poland, Romania, Slovakia, Spain, Sweden, 
Switzerland, and the United Kingdom (UK).
Box
ECDC guidance on public health management of sporadic 
cases of invasive meningococcal diseasea and risk 
assessment of infectious diseases transmitted on aircraftb
 ECDC guidance
•	 Chemoprophylaxis with an antibiotic regimen that 
eradicates carriage is recommended for household 
contacts of a case of IMD. (Strong recommendation)
•	 Sharing drinks, cigarettes or similar contact (implying 
a low level of salivary contact) with a case of IMD is 
not in itself an indication for chemoprophylaxis. (Weak 
recommendation)
•	 Attending the same preschool as a case of IMD is an 
indication for chemoprophylaxis, depending on risk 
assessment. (Weak recommendation)
•	 Attending the same school/college (including the same 
class) as a case of IMD is not in itself an indication for 
chemoprophylaxis. (Weak recommendation)
•	 Sharing the same transport vehicle as a case of IMD is 
not, in itself, an indication for chemoprophylaxis. (Weak 
recommendation)
•	 Rifampicin, ciprofloxacin, ceftriaxone, azithromycin 
and cefixime can be advised for chemoprophylaxis. 
(Strong recommendation) Ciprofloxacin, azithromycin 
and ceftriaxone are preferred. (Weak recommendation) 
In children, all these antibiotics can be advised. (Strong 
recommendation) In pregnant women, ceftriaxone, 
azithromycin and cefixime can be advised. (Weak 
recommendation)
•	 If a case of meningococcal disease is caused by a strain 
that is preventable by an available licensed vaccine, 
an appropriate course of vaccination – in addition to 
chemoprophylaxis – is recommended for household 
contacts unless considered to be protected by previous 
vaccination. (Strong recommendation)
RAGIDA
•	 Besides fellow travellers who may be household (-like) 
contacts of an index case, passengers and crew with close 
contact to pharyngeal secretions should be considered for 
contact tracing.
•	 Close contacts of IMD cases should be traced if the index 
cases were travelling while infectious (seven days before 
the onset of symptoms; up to 24 hours after the onset of 
effective treatment).
ECDC: European Centre for Disease Prevention and Control; 
IMD: invasive meningococcal disease; RAGIDA: risk 
assessment of infectious diseases transmitted on aircraft.
a Source: [10].
b Source: [13,14].
Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) [23] was used for ECDC guidance on public 
health management of IMD, but not in RAGIDA.
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Case definition criteria
There were only slight changes between 2007 and 2013 
for laboratory and other case definition criteria (Table 
1). The only case definition criterion for laboratory 
diagnosis used by all countries in 2013 was ‘isolation 
of Neisseria meningitidis from sterile site’, but a high 
proportion also used ‘isolation of meningococcal DNA 
from a sterile site’, ‘meningococcal antigen from CSF’ 
and ‘gram-negative diplococci from sterile site’.
Definition of close contacts
In 2013, 33 of 34 countries/regions recommended PEP 
to close contacts of an IMD case. This included all 23 
countries/regions that also participated in the 2007 
survey, when all respondents recommended PEP for 
close contacts after an IMD case (22/22; data miss-
ing for one country). However, the definition of close 
contact varied across countries/regions, with 11 of 34 
countries/regions including sharing cups and glasses 
with an index case and 23 of 34 kissing on the mouth 
(Table 2). The maximum period after contact with a 
case in which initiation of PEP was recommended var-
ied from seven days (n = 9/33) to one month (n = 5/33) 
(median 10 days; IQR 8–14).
Recommended chemoprophylaxis
Of the 33 countries/regions recommending PEP for 
close contacts of an IMD case in 2013, only one did 
not have specific guidelines on the choice of antibi-
otic for PEP. As in the 2007 survey, the most commonly 
recommended antibiotic in non-pregnant adults was 
ciprofloxacin (Table 3), most frequently administered 
as either 500 mg (26/29) or 750 mg (3/29), usually as 
a single dose (27/29), followed by rifampicin (usually 
as four 600 mg doses (26/27)). From 2007 to 2013, the 
proportion of countries/regions recommending use of 
ceftriaxone and azithromycin increased, but not sig-
nificantly (Table 3). In 2013, 29 of 34 countries/regions 
recommended PEP during pregnancy, most commonly 
intramuscular ceftriaxone (Table 3). One country addi-
tionally recommended cefixime in pregnancy and for 
children.
Most countries/regions recommended rifampicin as 
PEP for one year-old children both in 2007 and 2013 
(Table 3). Ciprofloxacin was recommended for this age 
in nine of 32 countries/regions in 2013 (starting from 
birth (4/9) or from one month (2/9) of age; the remain-
ing three countries did not specify a minimum age). In 
addition, two countries recommended ciprofloxacin in 
older children, one starting from the age of two and the 
other from the age of 14 years. The only statistically 
significant change from 2007 to 2013 was an increase 
in the proportion of countries/regions recommending 
ceftriaxone for one year-old children (Table 3).
A few countries/regions additionally recommended 
antibiotics not included in the guidance for various tar-
get groups, namely spiramycin (2/34), penicillin (4/34), 
cotrimoxazole (1/34) and ofloxacin (1/34).
Settings
In 2013, 32 of 34 countries/regions reported specific 
policies for PEP in preschool and school settings and 
33 of 34 in university settings. Twenty-two of 32 coun-
tries/regions recommended prophylaxis for all children 
sharing the same classroom following the occurrence of 
an IMD case in preschool. This increased significantly 
Table 1
Criteria for definition of IMD cases for the purpose of control measures in 2007 and 2013, European survey on public 
health policies for managing cases of meningococcal disease and their contacts, 2013 
Case definition criteria
Countries/regions applying 
criteria in 2013 (N = 34)
Countries/regions responding to both surveys 
and applying criteria  
2007 (N=23) and 2013 (N=23)
P value for 
comparison  
2007 vs 2013
n n (2007) n (2013)
Isolation of Neisseria meningitides from 
sterile site 34 22 23 1.000 
Isolation of meningococcal DNA from 
sterile site 32 20 22 0.608
Isolation of antigen from CSFa 32 19 21 0.665
Isolation of gram negative diplococci 
from sterile site 30 20 19 0.608
Detection of high titre in convalescent 
serum 2 6 2 0.243
Clinically compatible 21 16 13 0.542
Purpura fulminans 24 16 15 1.000
Official notification 15 12 9 0.554
CSF: cerebrospinal fluid; IMD: invasive meningococcal disease.
European Centre for Disease Prevention and Control (ECDC) or risk assessment guidelines for diseases transmitted on aircraft (RAGIDA) 
recommendations are highlighted in grey.
a This criterion differed slightly in the 2007 questionnaire: ‘Isolation of meningococcal antigen from sterile site’.
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Table 2
Criteria for definition of close contacts of IMD cases for the purpose of control measures in 2007 and 2013, European 
survey on public health policies for managing cases of meningococcal disease and their contacts, 2013
Definition of close 
contacts
Countries/regions applying 
criterion in 2013 (N = 34)
Countries/regions responding to both surveys and 
applying criterion in 
2007 (N=23) and 2013 (N=23)
P value for comparison  
2007 vs 2013
n n (2007) n (2013)
People sharing the 
same household 34 23 23 1.0 
People with 
equivalent level of 
close contact
30 22 22 1.0
Attending the same 
preschool facilitya 28 NA NA NA
Kissing on mouth 23 20 15 0.17
People sharing cups 
and glasses 11 9 5 0.34
Kissing on cheek 4 3 1 0.61
Period in which index patient is considered infectious 
7 days before onset 
of illness 21 14 14 1.0
10 days before 
onset of illness 10 7 8 1.0
ECDC: European Centre for Disease Prevention and Control; IMD: Invasive meningococcal disease; NA: not applicable; RAGIDA: Risk 
assessment guidelines for diseases transmitted on aircraft.
ECDC or RAGIDA recommendations are highlighted in grey.
a This criterion was not included in the 2007 questionnaire.
Table 3
Choice of post-exposure prophylaxis for contacts of IMD cases in different target groups, European survey on public health 
policies for managing cases of meningococcal disease and their contacts, 2013
Target group Antibiotic
Countries/regions 
recommending the antibiotic in 
2013 (N = 34)
Countries/regions responding to both surveys 
and recommending the antibiotic 
2007 (N=23) and 2013 (N=23)
P value for 
comparison  
2007 vs 2013
n n (2007) n (2013)
Adults 
Ciprofloxacin 29 20 21 1.0
Rifampicin 27 14 19 0.30
Ceftriaxone 22 13 15 0.76
Azithromycin 6 1 3 0.61
Children of one 
year of age 
Ciprofloxacin 9 5 7 0.75
Rifampicin 29 16 20 0.69
Ceftriaxone 21 6 15 0.03 
Azithromycin 6 3 4 1.0
Women in the 
first trimester 
of pregnancya 
Ciprofloxacin 2 0 2 0.49
Rifampicin 3 4 3 0.69
Ceftriaxone 25 12 18 0.21
Azithromycin 5 2 5 0.42
ECDC: European Centre for Disease Prevention and Control; IMD: invasive meningococcal disease; PEP: post-exposure prophylaxis.
a Number of countries that recommended specifically certain antibiotics for PEP in pregnancy in 2013: n = 27/34 (79%). In 2007 n = 18/23 vs 
n = 20/23 in 2013.
ECDC recommendations are highlighted in grey.
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from 2007 to 2013 in countries participating in both 
surveys (Table 4). In school and university settings, 
most countries/regions recommended PEP only to 
close contacts within the class (Table 4).
In 2013, 20 of 32 countries/regions recommended PEP 
to contacts after an IMD case on a plane either in gen-
eral or under specific circumstances (e.g. sitting next to 
the case, travel of a certain duration, overnight travel), 
a non-significant increase compared with 2007 (Table 
5). In 2013, of the 20 countries/regions that recom-
mended PEP after the occurrence of an IMD case on an 
aircraft, one implemented contact tracing for all pas-
sengers and 14 only for persons they considered eli-
gible for PEP (Table 5). Five countries strictly followed 
the criteria recommended by RAGIDA. Fifteen of 31 
countries/regions recommended PEP to contacts after 
an IMD case on a train or bus.
Vaccination
In 2007 eight of 23 countries recommended meningo-
coccal serogroup C vaccination in their national child-
hood vaccination programme, compared with 11 of 23 
in 2013. Of all respondents to the 2013 survey (n=34), 
18 countries/regions recommended serogroup C vacci-
nation in their routine schedule. Of these, five recom-
mended vaccination starting in the first six months of 
life and 13 at 12 months of age and older. Six countries/
regions recommended a booster dose for adolescents.
Vaccination of household contacts after the occur-
rence of an IMD case due to a vaccine-preventable 
serogroup was recommended by 24 of 34 countries/
regions in 2013. Among countries participating in both 
surveys, this increased slightly from 2007 (15/22) to 
2013 (17/22; p = 0.46). Of the 24 countries/regions rec-
ommending post-exposure vaccination in 2013, seven 
recommended this for close contacts after a serogroup 
C IMD case and 15 after an IMD case due to serogroups 
A, C, W or Y; serogroups were not specified by two 
countries. Countries/regions with meningococcal C 
vaccination in their childhood immunisation schedule 
were somewhat more likely to recommend post-expo-
sure vaccination (14/18) than countries/regions not 
having a routine childhood meningococcal vaccination 
policy (8/16, p = 0.15).
Perceived usefulness of ECDC guidance
Twenty-eight of 31 countries/regions found the ECDC 
guidance [12] document useful. Half (17/34) reported 
having used the ECDC guidance to update recommen-
dations in their country/region. The following topics 
were indicated as helpful: choice of medication for 
prophylaxis (4/17); management of contacts in trans-
port vehicles (4/17); increased emphasis on contact 
with pharyngeal secretions as a criterion for defining 
close contact (1/17); and criteria for laboratory diagno-
sis (1/17). Nine additional countries/regions stated they 
were planning to use the ECDC guidance document to 
update their country policy.
Cross border communication
In case of IMD occurring in a resident of another coun-
try, 28 of 32 countries/regions reported having a policy 
in place in 2013 for contacting the source country for 
contact tracing, if indicated. This was already the case 
for 19 out of 22 countries/regions in 2007. 
Discussion
Comparison of the results of the 2007 [12] and 2013 
surveys reveals increasing harmonisation of public 
health policies for the management of sporadic IMD 
cases and a relatively high level of adherence to evi-
dence-based guidance as published by ECDC in the 
period between the two surveys [10,13,14]. This applied 
to the two laboratory diagnostic case definition criteria 
considered to be gold standard [10], meningococcal 
culture and DNA isolation from a sterile site, and, in 
particular, to the choice of antibiotics for PEP and their 
use in preschools, elementary and secondary schools, 
and universities. Recommendations for the manage-
ment of contacts of an IMD case on transport vehicles 
remained heterogeneous, possibly reflecting the low 
level of evidence available in this area.
ECDC guidance [10,13,14] emphasises that exposure to 
respiratory droplets or pharyngeal secretions of a case 
is essential for the transmission of meningococcal dis-
ease. Thus, a casual social contact, even if involving 
sharing drinks or cigarettes, is not in itself an indica-
tion for PEP [10]. Although not statistically significant, 
fewer countries/regions considered such contacts 
to warrant a recommendation for PEP in 2007 than 
in 2013. In addition, ‘kissing on the mouth’ was also 
considered by fewer countries/regions in 2013 than in 
2007 to be a criterion for close contact. ECDC guidance 
states that exchange of pharyngeal secretions is likely 
to occur during intimate mouth-to-mouth kissing, which 
was found to be a risk factor for carriage or disease in 
observational studies [15-17]. However, a brief kiss on 
the mouth is unlikely to lead to significant exchange of 
pharyngeal secretions. Interpretation of our finding is 
difficult, as the wording of ‘kissing on the mouth’ was 
possibly interpreted to mean intimate mouth-to-mouth 
kissing by some, but not all countries/regions. Future 
surveys should define both types of kissing. In addi-
tion, we would like to stress that no contact indicator 
should be considered in isolation; rather, the overall 
contact history of each person must be evaluated to 
assess the likelihood of contact with pharyngeal secre-
tions of the index case.
As concluded in the ECDC guidance [10], none of the 
recommended regimens (rifampicin, ciprofloxacin, 
ceftriaxone, azithromycin and cefixime) can be con-
sidered superior in terms of effectiveness to eradicate 
meningococcal carriage [10,11]. However, ciprofloxa-
cin, azithromycin and ceftriaxone have the advantage 
of low reported rates of side effects and can be given 
as single dose, although the latter must be given intra-
muscularly [10]. Most countries/regions recommended 
ciprofloxacin and rifampicin, followed by ceftriaxone, 
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for adults. Despite rifampicin requiring four doses 
and being associated with the development of resist-
ance [11], most countries/regions still recommended it. 
Only four countries/regions specifically recommended 
single-dose ciprofloxacin or azithromycin and not 
rifampicin for adults.
Rifampicin was the antibiotic most commonly recom-
mended for children, followed by ceftriaxone, the rec-
ommendation for which significantly increased from 
2007 to 2013. Ciprofloxacin was recommended for PEP 
in children by nine of 32 countries/regions in 2013, 
with little change since 2007. Although ciprofloxacin is 
considered safe in children [10], reluctance to use this 
antibiotic is likely related to the warning of a theoreti-
cal risk of arthropathy in children in the product infor-
mation. In addition, ‘chemoprophylaxis of IMD’ is listed 
as an indication for adults, but not for children in the 
summary of product characteristics (SPC) for ciproflox-
acin [18]. In contrast, rifampicin is licensed for prophy-
laxis of meningococcal disease at all ages [10]. While 
ceftriaxone is not explicitly licensed for meningococcal 
prophylaxis, it is widely used for treatment of IMD.
We are not aware that meningococcal prophylaxis is 
included as an indication in the SPC of the other anti-
biotics for which there is evidence that they eradicate 
meningococcal carriage (azithromycin, cefixime). This, 
together with a lower level of evidence for the use of 
these antibiotics for prophylaxis, likely explains why 
only few countries/regions recommended these at 
all. Although the effectiveness of azithromycin and 
cefixime were comparable to rifampicin each in one 
randomised controlled trial [19,20], no trials compared 
these two antibiotics with placebo. In contrast, high 
eradication rates were shown for rifampicin, ciproflox-
acin and ceftriaxone in various randomised placebo-
controlled trials, providing a more robust evidence 
base [10]. Furthermore, while very low resistance rates 
have been reported for ciprofloxacin, rifampicin and 
ceftriaxone in European countries [1], routine sensitiv-
ity testing of N. meningitidis for azithromycin and cefix-
ime has not been widely implemented. Thus there is a 
paucity of data regarding development of resistance 
against these antibiotics, with no such data reported by 
EARS (European Antimicrobial Resistance Surveillance; 
hosted by ECDC) thus far [1,21]. Some countries/
regions recommended rifampicin and ciprofloxacin for 
Table 4
Use of post-exposure prophylaxis in IMD contacts in different educational settings, European survey on public health 
policies for managing cases of meningococcal disease and their contacts, 2013
Recommendation of chemoprophylaxis
Countries/regions applying 
recommendation in 2013 
(N = 32)a
Countries/regions responding to both 
surveys and applying recommendation 
2007 (N=23) and 2013 (N=23)
P value for comparison 
2007 vs 2013
n n (2007) n (2013)
Preschool 
For all children 5 3 2 1.0
for all children of the 
same group 22 8 17 0.02 
For close contacts in 
the same group 1 0 1 1.0
No chemoprophylaxis 3 12 3 0.01 
Elementary 
schoolb 
For all pupils 0 NA NA NA
For all pupils in the 
same class 7 NA NA NA
For close contacts in 
the same class 17 NA NA NA
No chemoprophylaxis 7 NA NA NA
Secondary 
schoolb 
For all pupils 0 NA NA NA
For all pupils attending 
the same class 6 NA NA NA
For close contacts in 
the same class 19 NA NA NA
No chemoprophylaxis 7 NA NA NA
Universityb 
For all students of the 
same class 1 NA NA NA
For close contacts in 
the same group 25 NA NA NA
No chemoprophylaxis 6 NA NA NA
ECDC: European Centre for Disease Prevention and Control; IMD: invasive meningococcal disease.
a Number of countries responding to the question on pre-, elementary and secondary school in 2013: n = 32; responding to questions on 
university settings: n = 33.
b This criterion was not included in the 2007 questionnaire.
ECDC recommendations are highlighted in grey.
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pregnant women despite theoretical risk to the foetus 
based on animal studies. Although this risk is consid-
ered low, the use of ceftriaxone, cefixime and azithro-
mycin in pregnancy is considered safer [10]. Finally, 
there is no supporting evidence to use antibiotics such 
as spiramycin, penicillin, cotrimoxazole and ofloxacin, 
still occasionally recommended for PEP in European 
countries [10].
The proportion of countries/regions recommending 
PEP in preschool settings increased significantly from 
2007 to 2013. This is in agreement with the weak rec-
ommendation in the ECDC guidance to provide PEP to 
contacts in the same preschool group, depending on 
risk assessment, despite availability of only low-qual-
ity evidence [10,22]. In older children and students 
most countries/regions only recommended PEP to 
close contacts within the class, also in agreement with 
ECDC guidance.
In 2013, about two-thirds of countries/regions recom-
mended PEP to contacts after a case on a plane in 
various circumstances. Risk of transmission of menin-
gococcal disease on airplanes is generally low [13] and 
sharing the same transport vehicle as an IMD case 
should not in itself justify PEP [10,14]. As in other set-
tings, contact with pharyngeal secretions of a case 
qualifies for the administration of chemoprophylaxis, 
yet this criterion played a role in only one quarter of 
countries/regions’ recommendations concerning air 
travel. However, RAGIDA does state that, based on 
expert opinion and given the severity of the disease, 
contact tracing can be considered for persons sitting 
next to the suspected or laboratory-confirmed case 
[13].
In spite of a strong recommendation for post-exposure 
vaccination for serogroups A, C, W and Y in addition to 
PEP [7,10], 10 of 34 countries/regions did not have a 
respective policy in place, with little change from 2007 
to 2013. This may be due to the very low level of evi-
dence behind this recommendation [10].
Communication between countries/regions in case of 
transborder IMD case management is an important 
issue given the steadily increasing mobility throughout 
Europe. Almost 90% of countries/regions reported hav-
ing a policy in place ensuring such communication. In 
addition, a high level of adherence to ECDC guidance in 
many areas – as observed in the 2013 survey – facili-
tates this task.
ECDC guidance on public health management of spo-
radic IMD was found useful by most participating coun-
tries/regions at the national level. However, only half 
of the countries/regions used the guidance to change 
Table 5
Criteria defining eligibility for post-exposure prophylaxis in countries/regions recommending chemoprophylaxis for fellow 
passengers of an IMD case on a plane, European survey on public health policies for managing cases of meningococcal 
disease and their contacts, 2013
Criteria for chemoprophylaxis in 
fellow passengers on a planea
Countries/regions applying 
criteria in 2013 
(N = 20)b
Countries/regions responding to both surveys 
and applying criteria 
2007 (N= 9)c and 2013 (N=13)c
P value for comparison 
2007 vs 2013
n n (2007) n (2013)
Duration of travel 
Four hours or more 2 2 23 1.0
Seven hours or more 1 1 0 0.41
Eight hours or more 8 3 5 1.0
Overnight travel 0 2 0 0.16
Time not taken into accountd 9 1 6 0.17
Proximity to the case 
Seated next to the case 6 4 4 0.66
Seated in the same row, row in 
front/back 7 1 4 0.61
Contact with pharyngeal 
secretions of the case 5 1 4 0.61
Undefined 2 3 1 0.26
ECDC: European Centre for Disease Prevention and Control; IMD: invasive meningococcal disease; RAGIDA: Risk assessment guidelines for 
diseases transmitted on aircraft.
a Responses were free-text in the 2007 questionnaire and multiple choice in the 2013 version.
b Countries/regions recommending post-exposure prophylaxis to passengers with contact to an IMD case on a plane in 2013: n = 20/32 (63%).
c Countries/regions recommending post-exposure prophylaxis to passengers with contact to an IMD case on a plane; 2007: n = 9/22 (41%); 
2013: n = 13/23 (57%).
d For 2007: time criteria not mentioned by one country.
ECDC or RAGIDA recommendations are highlighted in grey.
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recommendations. Besides, some of these countries 
having most recommendations already in place, a pos-
sible explanation is that the time interval between pub-
lication of the guidance and the survey was less than 
three years and may have been insufficient to achieve 
changes in national policies. This could explain per-
sistence of significant discrepancies between country 
recommendations, for instance in the management of 
contacts in schools and public transport vehicles and 
the vaccination of close contacts. It is likely that practi-
cal issues, policy constraints related to use of antibiot-
ics, reluctance to recommend antibiotics not explicitly 
licensed for PEP as well as economic considerations 
continue to contribute to these residual differences. 
In addition, some countries/regions may view recom-
mendations based on very low levels of evidence more 
critically than others; however, it is unlikely that higher 
level of evidence will be obtainable in most of these 
areas, as the very large studies that would be required 
are not feasible in a setting of overall low disease inci-
dence. Nonetheless, increasing awareness of available 
evidence, for instance through translation of guid-
ance documents into the respective languages, might 
improve adherence. It is also possible that the overall 
low incidence in European countries/regions may partly 
explain reluctance to adopt recommendations that con-
tribute with relatively low effectiveness to prevention 
of subsequent cases in the same setting. For instance, 
it has been estimated that to prevent one subsequent 
case, PEP must be administered to 300 household 
contacts, but to 1,900 same-group preschool contacts 
[10], and ca 1,000 household contacts need to be vac-
cinated [7].
There may be other reasons for persistent differences 
as well, such as logistic and economic considera-
tions related to the structure of a particular healthcare 
system that might influence the feasibility of imple-
menting certain public health measures even when 
recommended by international guidance. For instance, 
some antibiotics are more expensive than others or 
might be centrally procured at a reduced rate, and post-
exposure vaccination can be logistically challenging as 
vaccination may not be performed by the public health 
authority making the recommendation. Furthermore, 
countries may be reluctant to recommend antibiotics 
without routine resistance testing. All of these factors 
should be addressed in future similar surveys.
Comparisons between the two surveys were limited 
by the smaller number of countries/regions that par-
ticipated in 2007. Nonetheless, comparability between 
the surveys was high due to the similar method used 
and their being undertaken by almost the same team. 
The respective participants gave us information on 
the official national policy of their countries/regions. 
However, we could not assess to what extent policies 
were legally binding and actually implemented in the 
respective country. We tried to address this by care-
fully identifying the person best placed to participate 
for each country. Further research on the actual imple-
mentation of recommendations would be useful.
In conclusion, public health policies for the manage-
ment of sporadic IMD cases were better harmonised 
among European countries/regions in 2013 compared 
with 2007. This is notably reflected by good adher-
ence to evidence-based recommendations regarding 
the most important target groups requiring PEP as well 
as the choice of antibiotics for PEP published in 2010, 
suggesting that guidance disseminated by an inter-
national public health agency can have an important 
impact on public health policy. However, some dis-
crepancies remained, e.g. only a minority of countries/
regions strictly followed ECDC guidance for IMD con-
tacts in airplanes. Future surveys should specifically 
aim to identify possible reasons for persistent discrep-
ancies in public health management of IMD that might 
help achieve further harmonisation, as this is desirable 
in the context of increasing mobility across European 
societies.
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